Free tool
FAERS Monitor: Yuflyma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761219 or its brand name (Yuflyma, Adalimumab-Aaty). Reports on generic versions are filed under their own applications.
Reports
49,628
Serious
46,911
95% of reports
Hospitalization
17,132
Death reported
7,324
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,824
- off label use8,671
- rheumatoid arthritis6,004
- fatigue5,699
- pain5,648
- arthralgia5,415
- rash4,812
- condition aggravated4,734
- drug intolerance4,363
- nausea4,239
- headache4,231
- systemic lupus erythematosus4,230
- diarrhoea4,211
- joint swelling4,179
- treatment failure4,032
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 25 |
| 2006 | 10 |
| 2007 | 44 |
| 2008 | 136 |
| 2009 | 138 |
| 2010 | 257 |
| 2011 | 208 |
| 2012 | 256 |
| 2013 | 295 |
| 2014 | 277 |
| 2015 | 317 |
| 2016 | 504 |
| 2017 | 725 |
| 2018 | 1,254 |
| 2019 | 2,034 |
| 2020 | 2,716 |
| 2021 | 3,239 |
| 2022 | 4,585 |
| 2023 | 6,888 |
| 2024 | 8,971 |
| 2025 | 9,570 |
| 2026 | 7,171 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,531 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic lupus erythematosusSignal | 4,230 | 57.2 | 55.5 | 206,060 |
| rheumatoid arthritisSignal | 6,004 | 23.6 | 23.0 | 123,765 |
| treatment failureSignal | 4,032 | 21.6 | 21.0 | 75,755 |
| drug intoleranceSignal | 4,363 | 20.0 | 19.4 | 75,521 |
| joint swellingSignal | 4,179 | 15.2 | 14.7 | 53,663 |
| condition aggravatedSignal | 4,734 | 6.7 | 6.5 | 22,867 |
| arthralgiaSignal | 5,415 | 5.6 | 5.4 | 20,487 |
| rashSignal | 4,812 | 4.7 | 4.6 | 14,242 |
| off label useSignal | 8,671 | 4.2 | 4.1 | 22,081 |
| painSignal | 5,648 | 3.9 | 3.8 | 12,555 |
| drug ineffectiveSignal | 10,824 | 3.5 | 3.4 | 20,462 |
| fatigueSignal | 5,699 | 3.1 | 3.0 | 8,449 |
| headacheSignal | 4,231 | 2.9 | 2.8 | 5,286 |
| diarrhoeaSignal | 4,211 | 2.8 | 2.7 | 4,903 |
| nauseaSignal | 4,239 | 2.3 | 2.2 | 3,135 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.